{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:21:14Z","timestamp":1771464074709,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.transproceed.2023.12.019","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T02:29:04Z","timestamp":1708655344000},"page":"297-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Mycophenolate Mofetil In De Novo Renal Transplantation in a Retrospective Cohort of Transplant Recipients in Colombia\u2014Esmitren Study"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-9580","authenticated-orcid":false,"given":"Jose Nelson Carvajal","family":"Quiroz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Sebasti\u00e1n G\u00f3mez","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos Tob\u00f3n","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2023.12.019_bib0001","first-page":"213","article-title":"Inmunosupresi\u00f3n para receptores de trasplante renal: estrategias actuales","volume":"57","author":"Alber\u00fa","year":"2005","journal-title":"Revista de Investigaci\u00f3n Clinica"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0002","series-title":"Facultad De Medicina","article-title":"An\u00e1lisis del impacto de los niveles de f\u00e1rmacos inmunosupresores sobre los par\u00e1metros inmunol\u00f3gicos y bioqu\u00edmicos y su asociaci\u00f3n con infecci\u00f3n y rechazo en trasplante cardiaco","author":"Hern\u00e1ndez","year":"2018"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0003","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0006","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0009-9120(98)00040-X","article-title":"Therapeutic monitoring of mycophenolic acid a consensus panel report","volume":"31","author":"Shaw","year":"1998","journal-title":"Clin Biochem"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Onco Hematol"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0009","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/00007890-200006150-00033","article-title":"Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1600-6143.2005.00741.x","article-title":"Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis","volume":"5","author":"Lake","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0011","article-title":"Limited sampling strategy for estimation of mycophenolic acid exposure in adult Chinese heart transplant recipients","volume":"12","author":"Xiang","year":"2001","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0012","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00007691-199910000-00002","article-title":"Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase After renal transplantation: a longitudinal study in pediatric patients","volume":"21","author":"Weber","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0013","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00007691-200002000-00003","article-title":"Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation","volume":"22","author":"Shaw","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0014","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1345\/aph.1D099","article-title":"Mycophenolate pharmacokinetics in early period following lung or heart transplantation","volume":"37","author":"Ensom","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/j.1552-4604.2000.tb05988.x","article-title":"Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable","volume":"40","author":"Shaw","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0016","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1034\/j.1600-6143.2003.00079.x","article-title":"Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies","volume":"3","author":"Shaw","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007890-200107150-00014","article-title":"Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients","volume":"72","author":"Squifflet","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0009-9236(99)70012-3","article-title":"The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients","volume":"66","author":"Johnson","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0019","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.ftd.0000163949.40686.0f","article-title":"Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolatemofetil to heart transplant recipients","volume":"27","author":"Armstrong","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0020","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2174\/1389200219666171227201608","article-title":"Influence of genetic polymorphisms on mycophenolic acid pharmacokinetics and patient outcomes in renal transplantation","volume":"19","author":"Guo","year":"2018","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0021","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0022","unstructured":"CLAUSEN BIOSCIENCE. Bioequivalence Study of Suprimun\/Micoflavin\/Myclausen Tablets 500 mg vs. CellCept Tablets 500 mg. <https:\/\/docplayer.es\/2923064-Biociencia-clausen-bioequivalence-study-of-suprimun-micoflavin-myclausen-tablets-500-mg-vs-cellcept-tablets-500-mg.html>; [accessed 08.10.23]."},{"key":"10.1016\/j.transproceed.2023.12.019_bib0023","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1037\/a0024338","volume":"141","author":"Fritz","year":"2012","journal-title":"Journal of Experimental Psychology: General"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0024","unstructured":"Lenhard W, Lenhard A. Calculation of effect sizes. Retrieved from: <https:\/\/www.psychometrica.de\/effect_size.html.>; [accessed 08.10.23]."},{"key":"10.1016\/j.transproceed.2023.12.019_bib0025","doi-asserted-by":"crossref","first-page":"e13997","DOI":"10.1111\/ctr.13997","article-title":"A short overview on mycophenolic acid pharmacology and pharmacokinetics","volume":"34","author":"Ferreira","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0026","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/TP.0b013e3181744199","article-title":"Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review","volume":"85","author":"Knight","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0027","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1253\/circj.71.1022","article-title":"Limited sampling strategy for mycophenolic acid in Japanese hearttransplant recipients","volume":"71","author":"Wada","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0028","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/FTD.0b013e31817d7064","article-title":"Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients","volume":"30","author":"Kaczmarek","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0029","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.transproceed.2018.02.068","article-title":"Limited samplingstrategy for estimating mycophenolic acid exposure on day 7 post-transplant for two mycophenolate mofetil formulations derived from 20 Chinese renal transplant recipients","volume":"50","author":"Cai","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1053-2498(00)00191-1","article-title":"Mycophenolic acid concentrations are associated with cardiac allograft rejection","volume":"19","author":"DeNofrio","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0031","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.1111\/j.1432-2277.2000.tb02045.x","article-title":"Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil","volume":"13","author":"Brunet","year":"2000","journal-title":"Transplanta Int"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0032","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00007691-200004000-00005","article-title":"Limited sampling strategy for mycophenolic acid area under the curve","volume":"22","author":"Filler","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0033","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0009-9236(99)70012-3","article-title":"The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients","volume":"66","author":"Johnson","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0034","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0041-1345(98)00200-0","article-title":"Limited sampling strategy for the determinationof mycophenolic acid area under the curve in pediatric kidney recipients. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients","volume":"30","author":"Schutz","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-9120(00)00184-3","article-title":"Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients","volume":"34","author":"Shaw","year":"2001","journal-title":"Clin Biochem"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0036","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0041-1345(00)02322-8","article-title":"Monitoring of mycophenolic acid in pediatric renal transplant recipients","volume":"33","author":"Armstrong","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0037","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.V133759","article-title":"The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy","volume":"13","author":"Weber","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0038","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-6143.2005.01151.x","article-title":"Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity","volume":"6","author":"Borrows","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0039","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","article-title":"Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials","volume":"365","author":"Hodson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0040","first-page":"293","article-title":"Tratamiento profil\u00e1ctico por citomegalovirus en pacientes trasplantados renales mediante valganciclovir oral","volume":"28","author":"Guirado","year":"2008","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0041","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/0003-4819-143-12-200512200-00005","article-title":"Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients","volume":"143","author":"Kalil","year":"2005","journal-title":"Ann Int Med"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0042","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/TP.0000000000000522","article-title":"Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients","volume":"99","author":"Opeltz","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0043","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0044","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/01.TP.0000137105.92464.F3","article-title":"Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation","volume":"78","author":"Nett","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-014-0213-7","article-title":"Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients","volume":"54","author":"Tornatore","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0046","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.transproceed.2006.10.189","article-title":"Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?","volume":"39","author":"Arns","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0047","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","article-title":"Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management","volume":"24","author":"Behrend","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0048","doi-asserted-by":"crossref","first-page":"101","DOI":"10.14309\/crj.2016.13","article-title":"Severe enteropathy from mycophenolate mofetil","volume":"3","author":"Jehangir","year":"2016","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0049","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2011.01.002","article-title":"Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting","volume":"25","author":"Le Meur","year":"2011","journal-title":"Transplant Rev"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":"Therapeutic drug monitoring of mycophenolate mofetil in transplantation","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.transproceed.2023.12.019_bib0051","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.3390\/biomedicines10112882","article-title":"Individualization of mycophenolic acid therapy through pharmacogenetic, pharmacokinetic and pharmacodynamic testing","volume":"10","author":"Winnicki","year":"2022","journal-title":"Biomedicines"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134524000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134524000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:47:21Z","timestamp":1758577641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134524000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0041134524000733"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.12.019","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Mycophenolate Mofetil In De Novo Renal Transplantation in a Retrospective Cohort of Transplant Recipients in Colombia\u2014Esmitren Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}